Clinical Trial to evaluate the short duration treatment with Atosiban in Preterm Labor
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- 4. Proportion of women re-treated with atosiban
研究概览
简要总结
Aim& Objectives:
The aim of this study is to establish efficacy, safety andtolerability of atosiban in treatment of preterm labor.
Primary Objective
The primary objective is to evaluate the efficacy ofatosiban in delaying impending preterm birth
Secondary Objective
Toevaluate the safety and tolerability of atosiban in Indian women
StudyDesign:
Prospective, Open-label, Non-comparative study
EstimatedSample Size:
50 completed patients
Study Outcomes:
Primary outcome:
· Proportion of womenremaining undelivered at 13 hrs after start of atosiban treatment
· Evaluation of timegained in utero after initiationof treatment
· Percentage reduction inuterine contractions from baseline
· Proportion of womenre-treated with atosiban
· Proportion of womenre-treated with alternative tocolytic agent
Secondary outcomes:
· Proportion of maternaland fetal adverse events reported during the study period
研究设计
- 研究类型
- Interventional
- 分配方式
- Not Applicable
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 40.00 Year(s)(—)
- 性别
- Female
入选标准
- •1.Women ≥18 years of age 2.Gestational age from 24 until 33 completed weeks which has been documented by a definite LMP or sonography in the first trimester 3.Women with preterm labor.
- •The diagnosis of preterm labor requires the presence of ≥ 4 uterine contractions over 30 minutes, each lasting at least 30 seconds, and documented cervical change.
- •Criteria for cervical changes are defined as follows: a.Nulliparous women: a single cervical examination demonstrating dilatation of 0 cm to 3 cm and effacement of at least 50% b.Multiparous women: a single cervical examination demonstrating dilatation of 1 cm to 3 cm and effacement of at least 50%.
排除标准
- •1.Women with any of the following: a.Chorioamnionitis b.Preterm rupture of membranes c.Vaginal bleeding d.Eclampsia and severe pre-eclampsia requiring delivery e.Intrauterine growth restriction f.Intrauterine fetal death g.Congenital or acquired uterine malformation h.Severe placental insufficiency i.Placenta previa and abruptio placentae 2.Fetal distress 3.Women who are otherwise judged inappropriate for inclusion in the study by the investigator.
结局指标
主要结局
4. Proportion of women re-treated with atosiban
时间窗: 1.till the time of delivery
1. Proportion of women remaining undelivered at 13 hrs after start of atosiban treatment
时间窗: 1.till the time of delivery
3. Percentage reduction in uterine contractions from baseline
时间窗: 1.till the time of delivery
2. Evaluation of time gained in utero after initiation of treatment
时间窗: 1.till the time of delivery
5. Proportion of women re-treated with alternative tocolytic agent
时间窗: 1.till the time of delivery
次要结局
- 1. Proportion of maternal and fetal adverse events reported during the study period(till the time of delivery)
